|
Drug Delivery Technologies: Commercial Prospects 2010-2025Übersetzung: Medikamentenverabreichungs Technologien: kommerzielle Aussichten 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following benefits in particular:Our study gives you answers and trends - we aim to save you time and aid your decisions. You can have this report today Our new report can benefit everybody interested in drug delivery and related technologies. We forecast commercial potential, discovering trends. Do you want to harness those opportunities? You can stay ahead by ordering our report now. Please let us know how we can help. Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 168 Pages | |||||||||||
| Inhalt der Studie: |
How will the drug delivery sector develop from 2010, and where will you find the greatest opportunities? How will technology suppliers and drug companies benefit? We show you opportunities for revenue.....
How will the drug delivery sector develop from 2010, and where will you find the greatest opportunities? How will technology suppliers and drug companies benefit? We show you opportunities for revenue growth for suppliers and users of drug delivery technologies. You can have our report today, staying ahead. Our new report shows you trends to watch. Novel and generic drug producers can benefit from emerging and established drug delivery technologies. Developments will occur for biotech drugs and small-molecule agents. We analyse commercial trends for: • Oral drug delivery systems • Inhalation-based systems • Transdermal systems • Injectable systems • Implanted systems • Ocular and nasal systems. The market for drug delivery technologies has been growing rapidly, but which segments will grow fastest? What are the commercial trends to watch? How will the worldwide industry and market perform from 2010 to 2025? Our report answers those and other questions about this important pharma and biotech sector. We show how you can benefit from the sector. There remain unmet therapeutic needs. Drugs with improved delivery can gain significant market shares from 2010 onwards, increasing competitiveness and extending product lifecycles. The drug delivery industry and market can expand from 2010 onwards. Our report shows how you could benefit, saving your time and aiding your work. We show you opportunities by therapeutic area. You can find out how the drug delivery technology market will grow and study trends that are driving this sector. Our study will show you its technological and commercial potential from 2010 onwards. Industry and market analysis to save you time and aid your decisions Our new report examines the drug delivery sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses, pipeline developments and other data. You can discover strengths, weaknesses, opportunities and threats in the sector. We include 90 tables and figures and two expert interviews - shown in the contents lists with this message. Report Highlights Companies Listed 3M Drug Delivery Systems Abbott Laboratories Actelion Pharmaceuticals Alexion Pharmaceuticals Alimera Sciences Alkermes Alpha M.O.S. Altea Therapeutics Alvogen Amgen Amylin Pharmaceuticals Apotex Corp Applied Pharma Research (APR) Aradigm Corp AstraZeneca Bausch & Lomb Baxter International Bayer Biocon Biogen Idec Biotech Pharmaceuticals Boehringer Ingelheim Bristol-Myers Squibb Cardinal Health Catalent Pharma Solutions Celgene Corporation Cell Therapeutics Cephalon Chiron Corporation Cima Labs (Cephalon) Columbia Laboratories CSL Limited Dr. Reddy's Laboratories E. Merck KG EKR Therapeutics Elan Pharmaceuticals Eli Lilly and Company Elite Pharmaceuticals Emisphere Technologies Endo Pharmaceuticals Ethypharm Eurand Pharmaceuticals Eurofarma European Medicines Agency (EMA) Flynn Pharma Food and Drug Administration (US FDA) Fresenius Group Genentech (now part of Hoffmann-La Roche) Generex Biotechnology Corporation geneRx+ Genmab Genta Genzyme Corporation Gilead Sciences GlaxoSmithKline (GSK) Glycologic Limited Hisamitsu Pharmaceutical Co. Hoffmann-La Roche Intercell Johnson & Johnson Services (J&J) Labtec Leiras OY (Nycomed) MannKind Corporation MonoSol Rx MundiPharma Mylan NanoPass Technologies National Institute for Health and Clinical Excellence (NICE, UK) Nektar Therapeutics Novartis Pharma Noven Pharmaceuticals Novo Nordisk Novogyne Pharmaceuticals Otsuka Pharmaceuticals Co Pacira Pharmaceuticals Par Pharmaceutical Companies Penwest Pharmaceuticals Pfizer Pre-clinical Partnerships pSivida Corp. Ranbaxy Laboratories Roche Biomedical Laboratories Sanofi-Aventis Sanofi-Synthelabo (now Sanofi-Aventis) Schering-Plough Corporation (now part of Merck & Co.) Shire Sigma-Tau Pharmaceuticals SkyePharma Spectrum Pharmaceuticals Strativa Pharmaceuticals The Blackstone Group TRION Pharma UCB Vectura Group Whitehall Laboratories Wyeth (now a part of Pfizer) Zhejiang CONBA Pharmaceutical Co. [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Drug Delivery Technology Market Review 1.2 Aims, Scope and Format of the Report 1.3 Research & Analysis Methods 2. Introduction 2.1 Introduction to Drug Delivery Technologies (DDT) 2.2 Types of Technologies for Drug Delivery 2.2.1 Sustained/Controlled Release Systems 2.2.2 Injection 2.2.3 Needle-Free Injection 2.2.4 Pulmonary, Buccal and Nasal Delivery 2.2.5 Pills and Capsules 2.3 The World Biotech Market 2.3.1 Summary of the World Biotech Market 2.3.2 The Biotech Industry is Strong 2.4 Biotech Drugs with Associated Drug Delivery Technologies 2.4.1 Pegylated Interferons 2.4.2 A Crowded Insulin Market Has Forced Investment in DDT 2.5 Exubera - A Case Study for Alternative Biological Delivery Methods 2.5.1 Exubera, the First Inhaled Insulin 2.5.2 Description and Development History 2.5.3 Generex and MannKind Developing Next-Generation Oral Insulins 2.5.4 Cost, Caution and Complicated Dosing Could Restrict Afrezza and Oral-lyn 2.6 The Main Challenges for Biological Drug Delivery 3. Leading Markets for Drug Delivery Technology 3.1 The World Drug Delivery Technology Market in 2010 3.2 Growing Market for Drug Delivery Technology and Services 3.2.1 Revenue Forecast for Overall Drug Delivery Technology Market, 2010-2016 3.2.2 Revenue Forecast for Overall Drug Delivery Market, 2017-2025 3.3 Breakdown of the Global Drug Delivery Technology Market 3.3.1 Revenue Forecast for Oral Drug Delivery Technology, 2010-2016 3.3.2 Revenue Forecast for Oral Drug Delivery Technology, 2017-2025 3.3.3 Revenue Forecast for Inhalation Drug Delivery Technology, 2010-2016 3.3.4 Revenue Forecast for Inhalation Drug Delivery Technology, 2017-2025 3.3.5 Revenue Forecast for Transdermal Drug Delivery Technology, 2010-2016 3.3.6 Revenue Forecast for Transdermal Drug Delivery Technology, 2017-2025 3.3.7 Revenue Forecast for Injectable/Implant Drug Delivery Technology, 2010-2016 3.3.8 Revenue Forecast for Injectable/Implant Drug Delivery Technology, 2017-2025 3.3.9 Revenue Forecast for Ocular Drug Delivery Technology, 2010-2016 3.3.10 Revenue Forecast for Ocular Drug Delivery Technology, 2017-2025 3.3.11 Revenue Forecast for Nasal Drug Delivery Technology, 2010-2016 3.3.12 Revenue Forecast for Nasal Drug Delivery Technology, 2017-2025 3.4 National Markets for Drug Delivery Technology 3.4.1 Leading National Markets for Drug Delivery Technology, 2010-2025 3.4.2 The Japanese Drug Delivery Technology Market, 2010-2025 3.4.3 The Leading European Drug Delivery Technology Markets, 2010-2025 3.4.4 Emerging-Economy Drug Delivery Technology Markets 3.4.5 The Chinese Drug Delivery Technology Market, 2010-2025 3.4.6 The Indian Drug Delivery Technology Market, 2010-2025 4. Drug Classes that Can Benefit from Advances in Drug Delivery 4.1 Therapeutic Areas Offering Growth Opportunities 4.1.1 The Leading Biotech Therapy Classes, 2010-2025 4.1.2 The Top 10 Biotech Therapy Classes in 2009 4.1.3 The Oncology Class Currently Leads the Biotech Market 4.1.3.1 Long-Term Prospects in Oncology and Implications for the Drug Delivery Technology Market 4.1.4 The Human Insulins Class will Exhibit Strong Growth 4.1.5 Immunosuppressive Agents, 2010-2025 4.1.6 Autoimmune Agents Show Promising Growth - Will it Last? 4.1.7 Erythropoietin Products - How Will Reported Safety Affect Sales? 4.1.7.1 Erythropoietin Products Forecast, 2010-2025 4.1.8 Immunostimulating Agents - Sales Prospects 4.1.9 The Interferons Class Will Show an Increase in Revenues from 2010-2015 4.1.9.1 Long-Term Forecast for the Interferons Class 4.1.10 Vaccine Sales 4.1.10.1 Will Pure Vaccine Sales Decline from 2015? 4.1.11 Blood Coagulation Factors Will Show Steady Growth 4.1.12 Growth Hormones Forecast, 2010-2025 4.2 Summary of World Market Forecasts 4.2.1 Top 10 Biotech Therapy Classes, 2010-2025 4.2.2 Drug Delivery Technology Market: a Rapidly-Expanding Segment of the Global Pharma Sector 5. Some Prominent Companies in the Drug Delivery Technology Market 5.1 Introduction 5.2 Leading Oral Drug Delivery Companies 5.2.1 Applied Pharma Research (APR) 5.2.1.1 Overview 5.2.1.2 Therapeutic Areas and Technology 5.2.1.3 MonoSol Rx Announces FDA Approval of Zuplenz: An Oral Soluble Film for Treatment of Nausea and Vomiting 5.2.2 Catalent Pharma Solutions 5.2.2.1 Overview 5.2.2.2 Catalent's Oral Drug Delivery Technology 5.2.2.3 Catalent's Customer Base 5.2.2.4 Manufacturing Capabilities 5.2.2.5 Revenues 5.2.3 Emisphere Technologies 5.2.3.1 Overview 5.2.3.2 Emisphere's Eligen Technology 5.2.3.3 Emisphere's Pipeline Products 5.2.3.4 Emisphere's Partnered Programmes 5.2.3.5 Revenues 5.2.3.6 Future Outlook 5.2.4 Ethypharm 5.2.4.1 Overview 5.2.4.2 Ethypharm's Proprietary Technologies 5.2.4.3 Products on the Market 5.2.5 Eurand 5.2.5.1 Overview 5.2.5.2 Eurand's Drug Delivery Platforms 5.2.5.3 Pipeline Products/Indication 5.2.5.4 Revenue 5.2.5.5 Future Outlook 5.2.6 Glycologic Limited 5.2.6.1 Overview 5.2.6.2 Glycologic Technology Platform 5.2.6.3 Pipeline Products 5.2.6.4 Future Outlook 5.2.7 Penwest Pharmaceuticals 5.2.7.1 Overview 5.2.7.2 Penwest's Technology Platforms 5.2.7.3 Pipeline Products 5.2.7.4 Penwest's IP and Patents 5.2.7.5 Revenues 5.3 Inhaled Drug Delivery 5.3.1 3M Drug Delivery Systems 5.3.1.1 Overview 5.3.1.2 Protein and Peptide Delivery 5.3.1.3 Excipient Technology for CFC-Free Inhalers 5.3.1.4 Actuator Technology for MDIs 5.3.1.5 Particle Engineering Technology 5.3.1.6 Revenues 5.3.2 Aradigm Corp. 5.3.2.1 Overview 5.3.2.2 AERx Drug Delivery System 5.3.2.3 Aradigm Collaborations 5.3.2.4 Pipeline Products 5.3.2.5 Revenues 5.3.3 Vectura Group 5.3.3.1 Overview 5.3.3.2 Proprietary Technologies 5.3.3.3 Pipeline Products 5.3.3.4 Revenues 5.4 Injectable Drug Delivery 5.4.1 Alkermes 5.4.1.1 Overview 5.4.1.2 Proprietary Technology Platforms 5.4.1.3 Product Pipeline 5.4.1.4 Revenues 5.4.2 Pacira Pharmaceuticals 5.4.2.1 Overview 5.4.2.2 Injectable Sustained-Release Technology 5.4.2.3 Products 5.4.2.4 Pipeline 5.4.2.5 Revenues 5.4.2.6 Future Outlook 5.5 Transdermal Drug Delivery 5.5.1 3M 5.5.1.1 Overview 5.5.1.2 Transdermal Systems 5.5.2 Altea Therapeutics 5.5.2.1 Overview 5.5.2.2 Altea's PassPort Technology Platform 5.5.2.3 Therapeutic Focus 5.5.3 Intercell 5.5.3.1 Overview 5.5.3.2 Vaccine Patch Technology Platform 5.5.3.3 Intercell's Strategic Alliances 5.5.3.4 Revenues 5.5.4 NanoPass Technologies 5.5.4.1 Overview 5.5.4.2 Technology Platform 5.5.4.3 The MicronJet Needle 5.5.5 Noven Pharmaceuticals 5.5.5.1 Overview 5.5.5.2 Key Products 5.5.5.3 Transdermal Pipeline Products 5.5.5.4 Revenues 5.6 Transmucosal Drug Delivery 5.6.1 Overview 5.6.2 Cima Labs (Cephalon) 5.6.2.1 Overview 5.6.2.2 Cima's Transmucosal Drug Delivery Technologies 5.6.2.3 Products 5.6.3 Columbia Laboratories 5.6.3.1 Overview 5.6.3.2 Bioadhesive Delivery Technology 5.6.3.3 Products 5.6.3.4 Revenue 5.6.4 Generex Biotechnology Corporation 5.6.4.1 Overview 5.6.4.2 Products 5.6.4.3 Pipeline Products 5.6.4.4 Revenue 5.7 Implant Technology 5.7.1 Overview 5.7.2 pSivida Corp. 5.7.2.1 Overview 5.7.2.2 Technologies and Products 5.7.2.2.1 Durasert Technology System 5.7.2.2.2 BioSilicon Technology System 5.7.2.2.3 CODRUG Technology System 5.7.2.3 Products 5.7.2.4 Revenues 6. Drivers, Restraints and Trends in Drug Delivery 6.1 Analysis of Strengths, Weaknesses, Opportunities and Threats (SWOT), 2010-2025 6.2 Patent Expiry Will Drive Biological Drug Delivery 6.2.1 Biosimilars Legislation Encourages Innovation 6.2.2 As Patents Expire, Competition Will Increase 6.3 Competitive and Lucrative Monoclonal Antibody Market Will Drive Sales 6.4 Biological Drug Delivery Technology is Already Established 6.4.1 Controlled-Release Technologies 6.4.2 Exubera, Afrezza and Oral-lyn Show the Way for Innovative Technologies 6.4.3 The Emerging Nanotech Industry is Good News for Biological Drug Delivery 6.5 Will Regulatory Authorities Hold Back the Market? 6.5.1 Risk-Conscious FDA and EMA Will Make Approval Difficult? 6.5.2 Choice Between New Technology or a New Drug? Is a Rethink Required? 6.6 New Delivery Methods for Biologicals Must be Cost-Effective and Appropriate 6.7 Injection is Still the Main Form of Delivery 6.8 Next-Generation Drugs May Limit Drug-Delivery Revenues 6.8.1 Lifecycle Management via Protein Engineering Blurs Drug Delivery Lines 6.8.2 New Chemical Entities Could Restrict Biotech Growth 6.9 The Biological Drug Delivery Market Offers Great Potential, But Care is Required 7. Expert Views from the Sector 7.1 Expert Interview 1: Professor Sven Frøkjær, Dean, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark 7.1.1 Current Market Value for Drug Delivery Systems 7.1.2 Key Benefits for Patients 7.1.3 On Emerging Technologies 7.1.4 On Nanotechnology 7.1.5 On Different Systems 7.1.6 Main Challenges Facing the Sector 7.1.7 On Nanoparticle Systems and Drug Delivery 7.1.8 Systems on the Market 7.1.9 Diseases of Interest 7.1.10 Therapeutic Areas Offering Opportunities 7.2 Expert Interview 2: Dr Bill Lambert, PhD, Senior Vice President, Pharmaceutical Development, Pacira Pharmaceuticals, San Diego, CA, USA 7.2.1 On Pacira and Drug Delivery Technology 7.2.2 Liposomal Drug Delivery 7.2.3 Applications of DepoFoam Technology 7.2.4 On Pacira's Products 7.2.5 Pipeline DDT Platforms 7.2.6 On the Market for Drug Delivery Technology 7.2.7 Therapeutic Areas Offering Market Opportunities 7.2.8 Challenges Facing the Drug Delivery Industry 7.2.9 Comparing DepoFoam with Other Controlled-Release Systems 7.2.10 Mode of Delivery 7.2.11 Insulin and Liposomal Drug Delivery 7.2.12 R&D and Technologies Likely to be on the Market in Future 8. Conclusions 8.1 The Market Shows Great Potential 8.2 Commercial Drivers for Drug Delivery Technology 8.3 Prominent Companies in the Market 8.4 Future Outlook and Concluding Remarks [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Top 10 Biotech Products on the Market, 2009 Table 2.2 Top 10 Biotech Companies, Revenues, 2008 and 2009 Table 2.3 Amino Acid Changes for Human Insulin Analogues Table 3.1 Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.2 Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.3 Oral Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.5 Inhalation Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.6 Inhalation Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.7 Transdermal DDT Market: World Revenues, 2009-2016 Table 3.8 Transdermal DDT Market: World Revenues, 2017-2025 Table 3.9 Injectable/Implants DDT Market: World Revenues, 2009-2016 Table 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2025 Table 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.15 Drug Delivery Technology Market: World Revenues, 2009-2016 Table 3.16 Drug Delivery Technology Market: World Revenues, 2017-2025 Table 3.17 Leading Drug Delivery Technology National Markets: Revenues, 2009-2015, 2020 & 2025 Table 4.1 The Top 10 Biotech Therapy Classes, 2009 Table 4.2 Oncology Class: World Sales, 2009-2016 Table 4.3 Oncology Class: World Sales, 2017-2025 Table 4.4 Human Insulins Class: World Sales, 2009-2016 Table 4.5 Human Insulins Class: World Sales, 2017-2025 Table 4.6 Immunosuppressive Agents Class: World Sales, 2009-2016 Table 4.7 Immunosuppressive Agents Class: World Sales, 2017-2025 Table 4.8 Autoimmune Agents Class: World Sales, 2009-2016 Table 4.9 Autoimmune Agents Class: World Sales, 2017-2025 Table 4.10 Erythropoietin Products Class: World Sales, 2009-2016 Table 4.11 Erythropoietin Products Class: World Sales, 2017-2025 Table 4.12 Immunostimulating Agents Class: World Sales, 2009-2016 Table 4.13 Immunostimulating Agents Class: World Sales, 2017-2025 Table 4.14 Interferons Class: World Sales, 2009-2016 Table 4.15 Interferons Class: World Sales, 2017-2025 Table 4.16 Pure Vaccines Class: World Sales, 2009-2016 Table 4.17 Pure Vaccines Class: World Sales, 2017-2025 Table 4.18 Blood Coagulation Factors Class: World Sales, 2009-2016 Table 4.19 Blood Coagulation Factors Class: World Sales, 2017-2025 Table 4.20 Growth Hormones Class: World Sales, 2009-2016 Table 4.21 Growth Hormones Class: World Sales, 2017-2025 Table 4.22 Leading Biotech Therapy Classes: World Sales, 2009-2016 Table 4.23 Leading Biotech Therapy Classes: World Sales, 2017-2025 Table 5.1 Approved Drugs Using Penwest's TIMERx Technology, 2010 Table 5.2 Penwest's Product Pipeline, 2010 Table 5.3 Alkermes' Product Pipeline, 2010 Table 5.4 Noven's Marketed Transdermal Products, 2010 Table 6.1 SWOT Analysis for the Drug Delivery Sector, 2010 Table 6.2 Some Leading Drugs Losing Patent Protection, 2010-2012 Table 6.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003 Table 6.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2010 Table 6.5 Leading Biologic Drug Types, 2009 Table 8.1 Drug Delivery Technology Market: World Revenues, 2009, 2010, 2012, 2015, 2018, 2020 & 2025 Figure 3.1 Drug Delivery Technology Market: World Revenues, 2009-2016 Figure 3.2 Drug Delivery Technology Market: World Revenues, 2017-2025 Figure 3.3 Oral Drug Delivery Technology Market: World Revenues, 2009-2016 Figure 3.4 Oral Drug Delivery Technology Market: World Revenues, 2017-2025 Figure 3.5 Inhalation DDT Market: World Revenues, 2009-2016 Figure 3.6 Inhalation DDT Market: World Revenues, 2017-2025 Figure 3.7 Transdermal DDT Market: World Revenues, 2009-2016 Figure 3.8 Transdermal DDT Market: World Revenues, 2017-2025 Figure 3.9 Injectable/Implants DDT Market: World Revenues, 2009-2016 Figure 3.10 Injectable/Implants DDT Market: World Revenues, 2017-2025 Figure 3.11 Ocular Drug Delivery Technology Market: World Revenues, 2009-2016 Figure 3.12 Ocular Drug Delivery Technology Market: World Revenues, 2017-2025 Figure 3.13 Nasal Drug Delivery Technology Market: World Revenues, 2009-2016 Figure 3.14 Nasal Drug Delivery Technology Market: World Revenues, 2017-2025 Figure 3.15 Drug Delivery Technology Market: World Revenues, 2009-2025 Figure 3.16 US DDT Market: Revenues, 2009-2025 Figure 3.17 Other Leading DDT National Markets: Revenues, 2009-2025 Figure 3.18 DDT Revenue Shares for Leading National Markets, 2010 Figure 3.19 DDT Revenue Shares for Leading National Markets, 2015 Figure 3.20 DDT Revenue Shares for Leading National Markets, 2020 Figure 3.21 DDT Revenue Shares for Leading National Markets, 2025 Figure 4.1 Oncology Class: World Sales, 2009-2025 Figure 4.2 Human Insulins Class: World Sales, 2009-2025 Figure 4.3 Immunosuppressive Agents Class: World Sales, 2009-2025 Figure 4.4 Autoimmune Agents Class: World Sales, 2009-2025 Figure 4.5 Erythropoietin Products Class: World Sales, 2009-2025 Figure 4.6 Immunostimulating Agents Class: World Sales, 2009-2025 Figure 4.7 Interferons Class: World Sales, 2009-2025 Figure 4.8 Pure Vaccines Class: World Sales, 2009-2025 Figure 4.9 Blood Coagulation Factors Class: World Sales, 2009-2025 Figure 4.10 Growth Hormones Class: World Sales, 2009-2025 Figure 4.11 Leading Biotech Therapy Classes: World Sales, 2009-2025 Figure 4.12 Top Ten Therapy Classes: World Sales, 2009, 2015 & 2025 Figure 6.1 Different Approaches to Biological Drug Delivery Figure 8.1 Drug Delivery Technology Market: World Revenue Forecasts by Category, 2009, 2010, 2012, 2015, 2018, 2020 & 2025 Figure 8.2 Drug Delivery Technology Market: Overall World Revenue Forecast, 2009, 2010, 2012, 2015, 2018, 2020 & 2025 Figure 8.3 Drug Delivery Technology Market: World Revenue Shares by Category, 2010 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
